Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Link
http://academic.oup.com/annonc/article-pdf/29/1/209/23561086/mdx680.pdf
Reference28 articles.
1. Testicular cancer–discoveries and updates;Hanna;N Engl J Med,2014
2. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors;Einhorn;N Engl J Med,2007
3. TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis;Feldman;J Clin Oncol,2010
4. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors;Kondagunta;J Clin Oncol,2005
5. VP-16 plus ifosfamide plus cisplatin as salvage therapy in refractory germ cell cancer;Loehrer;J Clin Oncol,1986
Cited by 146 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Clinical outcome and prognostic factors for immunotherapy-based treatments in patients with platinum-refractory germ cell tumor;International Immunopharmacology;2024-12
2. Unwrapping the immunological alterations in testicular germ cell tumors: From immune homeostasis to malignancy and emerging immunotherapies;Andrology;2024-09-10
3. The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis;Cancer Treatment Reviews;2024-09
4. High-dose chemotherapy with autologous stem cell transplants in adult primary non-seminoma mediastinal germ-cell tumors. A report from the Cellular Therapy and Immunobiology working party of the EBMT;ESMO Open;2024-09
5. Single‐cell transcriptomic analysis reveals that the APP–CD74 axis promotes immunosuppression and progression of testicular tumors;The Journal of Pathology;2024-08-19
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3